LANGHORNE, Pa., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company"), today announced that its UltraMIST® Ultrasound Healing Therapy System received a GOOD DESIGN® Award. The GOOD DESIGN Awards are presented by The Chicago Athenaeum Museum of Architecture and Design and the Metropolitan Arts Press Ltd to the world’s leading designers to acknowledge creativity, modernization, advancement and outstanding products that stretch the boundaries of average design.
The UltraMIST System is Alliqua’s latest addition to its line of MIST® Therapy products. MIST Therapy involves the use of noncontact, low-frequency ultrasound delivered through a saline mist to accelerate wound healing. Unlike conventional wound treatments that are limited to treating the surface, MIST Therapy delivers ultrasound energy into and below the wound bed to stimulate cells and shorten the healing process. Over 1.4 million MIST Therapy treatments have been performed to date benefiting a wide range of patients. The UltraMIST System was developed in conjunction with Logic PD, a local engineering design house known for its expertise with medical devices.
“In the U.S. alone, up to $25 billion is spent each year to treat chronic, non-healing wounds,” stated Nino Pionati, Chief Strategy and Marketing Officer of Alliqua BioMedical, Inc. “Reducing healthcare expenditures and improving patient quality of care in this field requires technologies that both reduce the time-to-heal and are easy for healthcare providers to use. By incorporating state-of-the-art ultrasonic technology into a small, sleek and user-friendly design, the UltraMIST System offers practitioners an easy way to promote healing in a wide variety of chronic wounds. We are therefore pleased that the excellent design and development work that went into this project has been recognized by such an award.”
About Alliqua BioMedical, Inc.
Alliqua is a provider of advanced wound care solutions, committed to restoring tissue and rebuilding lives. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds.
Alliqua currently markets its line of dressings for wound care under the SilverSeal® and Hydress® brands, as well as the sorbion sachet S® and sorbion sana® wound care products, and its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology. The Company's Mist Therapy System® uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed to promote the healing process. Alliqua also markets the human biologic wound care product Biovance®.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its hydrogel technology. Alliqua's electron beam production process, located at its 16,500 square foot Good Manufacturing Practice (GMP) manufacturing facility, allows Alliqua to custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries. The Company has locations in Langhorne, PA and Eden Prairie, MN.
Legal Notice Regarding Forward-Looking Statements:
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, the adequacy of the Company’s liquidity to pursue its complete business objectives; inadequate capital; the Company’s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key customer or supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; price increases for supplies and components; and the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in our filings with the SEC, including our most recent Annual Report on Form 10-K filed with the SEC, and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
CONTACT: Investor Relations: Westwicke Partners on behalf of Alliqua Biomedical, Inc. Mike Piccinino, CFA +1-443-213-0500 AlliquaBiomedical@westwicke.com
Source:Alliqua BioMedical, Inc